Screener / SEC EDGAR /CIK 0001604821 /10-K filed Feb 27, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Labs

Natera, Inc. NTRA

Compare with peers Embed
Planned sales, announced before they happen

13 trading plans running, 106 Form 144 notices for $322.1M

10-Q, 10-K and Form 144
Plans running now 13 Daniel Rabinowitz, John Fesko, Matthew Rabinowitz, Steve Chapman, Jonathan Sheena, Rowan Chapman, Herm Rosenman, Mike Brophy, Roy Baynes
Plans adopted 27 reported since May 10, 2023 Form 144 notices 106 $322.1M the sellers expected to sell

What NTRA's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From Dec 10, 2025 to Sep 12, 2028. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.

InsiderWhatDateReported in
Daniel Rabinowitz
chief legal officer and secretary
Adopted 10b5-1 plan Sep 14, 2026 10-Q Nov 5, 2026
What the company wrote
On September 14, 2026, Daniel Rabinowitz, our chief legal officer and secretary, adopted a Rule 10b5-1 Trading Plan that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Rabinowitz’s Rule 10b5-1 Trading Plan provides for the potential sale of up to 60,000 shares of our common stock pursuant to the terms of the plan between January 2, 2027 and December 31, 2028.
John Fesko
chief business officer
Adopted 10b5-1 plan Sep 14, 2026 10-Q Nov 5, 2026
What the company wrote
On September 14, 2026, John Fesko, our chief business officer, adopted a Rule 10b5-1 Trading Plan that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Fesko’s Rule 10b5-1 Trading Plan provides for the potential sale of up to 90,000 shares of our common stock pursuant to the terms of the plan between December 14, 2026 and December 31, 2027.
Matthew Rabinowitz
executive chairman
Adopted 10b5-1 plan Sep 14, 2026 10-Q Nov 5, 2026
What the company wrote
On September 14, 2026, Matthew Rabinowitz, our executive chairman, adopted a trading arrangement for the sale of shares of our common stock (a “Rule 10b5-1 Trading Plan”) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Dr. Rabinowitz’s Rule 10b5-1 Trading Plan provides for the potential sale of up to 200,000 shares of our common stock pursuant to the terms of the plan between January 19, 2027 and July 19, 2027.
Matthew Rabinowitz
executive chairman
Adopted 10b5-1 plan Jun 12, 2026 10-Q Aug 7, 2026
What the company wrote
On June 12, 2026, Matthew Rabinowitz, our executive chairman, adopted a trading arrangement for the sale of shares of our common stock (a “Rule 10b5-1 Trading Plan”) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Dr. Rabinowitz’ Rule 10b5-1 Trading Plan provides for the potential sale of up to 200,000 shares of our common stock pursuant to the terms of the plan between September 11, 2026 and February 19, 2027.
Matthew Rabinowitz
executive chairman
Adopted 10b5-1 plan Mar 13, 2026 10-Q May 8, 2026
What the company wrote
On March 13, 2026, Matthew Rabinowitz, our executive chairman, adopted a trading arrangement for the sale of shares of our common stock (a “Rule 10b5-1 Trading Plan”) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Dr. Rabinowitz’ Rule 10b5-1 Trading Plan provides for the potential sale of up to 100,000 shares of our common stock pursuant to the terms of the plan between June 12, 2026 and December 17, 2026.
Steve Chapman
chief executive officer
Adopted 10b5-1 plan Mar 5, 2026 10-Q May 8, 2026
What the company wrote
On March 5, 2026, Steve Chapman, our chief executive officer, modified a Rule 10b5-1 Trading Plan to provide for the potential sale of 180,643 shares of our common stock pursuant to the terms of the plan between June 4, 2026 and March 31, 2028. A significant portion of the shares subject to the plan would not be sold unless the Company achieves specified performance targets.
Jonathan Sheena
member of our board of directors
Adopted 10b5-1 plan Dec 12, 2025 10-K Feb 27, 2026
What the company wrote
On December 12, 2025, Jonathan Sheena, a member of our board of directors, adopted a Rule 10b5-1 Trading Plan that provides for the sale of 59,000 shares of our common stock pursuant to the terms of the plan between May 8, 2026 and June 21, 2027.
Rowan Chapman
a member of our board of directors
Adopted 10b5-1 plan Dec 12, 2025 10-K Feb 27, 2026
What the company wrote
On December 12, 2025, Rowan Chapman, a member of our board of directors, adopted a Rule 10b5-1 Trading Plan that provides for the sale of 3,221 shares of our common stock pursuant to the terms of the plan between March 13, 2026 and December 1, 2026.
Matthew Rabinowitz
our co-founder and executive chairman
Adopted 10b5-1 plan Dec 11, 2025 10-K Feb 27, 2026
What the company wrote
On December 11, 2025, Matthew Rabinowitz, our co-founder and executive chairman, adopted a Rule 10b5-1 Trading Plan that provides for the sale of 200,000 shares of our common stock pursuant to the terms of the plan between March 12, 2026 and August 31, 2026.
Herm Rosenman
a member of our board of directors
Adopted 10b5-1 plan Dec 10, 2025 10-K Feb 27, 2026
What the company wrote
On December 10, 2025, Herm Rosenman, a member of our board of directors, adopted a Rule 10b5-1 Trading Plan that provides for the exercise of 16,530 stock options and sale of underlying shares of our common stock pursuant to the terms of the plan between March 11, 2026 and December 10, 2026.
Daniel Rabinowitz
our chief legal officer
Adopted 10b5-1 plan Dec 5, 2025 10-K Feb 27, 2026
What the company wrote
Insider Trading Arrangements and Policies ​ On December 5, 2025, Daniel Rabinowitz, our chief legal officer, adopted a trading arrangement for the sale of shares of the Company’s common stock intended to satisfy the affirmative defense of Rule 10b5-1(c) (a “Rule 10b5-1 Trading Plan”) that provides for the sale of 61,600 shares of our common stock and the exercise of 5,598 stock options and sale of underlying shares of our common stock, pursuant to the terms of the plan between March 6, 2026 and December 5, 2027.
Mike Brophy
chief financial officer
Adopted 10b5-1 plan Sep 10, 2025 10-Q Nov 7, 2025
What the company wrote
On September 10, 2025, Mike Brophy, our chief financial officer, amended a Rule 10b5-1 Trading Plan to provide for the potential sale of up to 128,846 shares of our common stock pursuant to the terms of the plan between February 2, 2026 and February 8, 2028. A significant portion of the shares subject to the plan would not be sold unless the Company achieves specified performance targets.
Roy Baynes
a member of the Company’s board of directors
Adopted 10b5-1 plan Aug 20, 2025 10-Q Nov 7, 2025
What the company wrote
On August 20, 2025, Roy Baynes, a member of the Company’s board of directors, adopted a trading arrangement for the sale of securities of the Company’s common stock (a “Rule 10b5-1 Trading Plan”) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Baynes’ Rule 10b5-1 Trading Plan provides for the exercise of 12,780 stock options and sale of underlying shares of common stock pursuant to the terms of the plan, between November 19, 2025 and August 31, 2027.
Mike Brophy
chief financial officer
Adopted 10b5-1 plan Jun 10, 2025 10-Q Aug 8, 2025
What the company wrote
On June 10, 2025, Mike Brophy, our chief financial officer, adopted a trading arrangement for the sale of securities of the Company’s common stock (a “Rule 10b5-1 Trading Plan”) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Brophy’s Rule 10b5-1 Trading Plan provides for the sale of up to 122,596 shares of common stock pursuant to the terms of the plan between February 2, 2026 and February 8, 2028.
Gail Marcus
member of our board of directors
Adopted 10b5-1 plan Dec 11, 2024 10-K Feb 28, 2025
What the company wrote
​ On December 11, 2024, Gail Marcus, a member of our board of directors, adopted a Rule 10b5-1 Trading Plan that provides for the sale of 6,618 shares of our common stock and the exercise of 16,299 stock options and sale of underlying shares of our common stock, pursuant to the terms of the plan between March 12, 2025 and December 31, 2025.
Jonathan Sheena
co-founder and a member of our board of directors
Adopted 10b5-1 plan Dec 11, 2024 10-K Feb 28, 2025
What the company wrote
​ On December 11, 2024, Jonathan Sheena, our co-founder and a member of our board of directors, adopted a Rule 10b5-1 Trading Plan that provides for the sale of 49,911 shares of our common stock pursuant to the terms of the plan between April 4, 2025 and April 29, 2026.
Matthew Rabinowitz
co-founder and executive chairman
Adopted 10b5-1 plan Dec 3, 2024 10-K Feb 28, 2025
What the company wrote
​ On December 3, 2024, Matthew Rabinowitz, adopted a Rule 10b5-1 Trading Plan that provides for the sale of 130,000 shares of our common stock pursuant to the terms of the plan between March 4, 2025 and August 23, 2025.
Solomon Moshkevich
president
Adopted 10b5-1 plan Nov 26, 2024 10-K Feb 28, 2025
What the company wrote
​
Roy Baynes
member of our Board of Directors
Adopted 10b5-1 plan Aug 12, 2024 10-Q Nov 12, 2024
What the company wrote
On August 12, 2024 , Roy Baynes , a member of our Board of Directors , adopted a trading arrangement for the sale of shares of our common stock (a “Rule 10b5-1 Trading Plan”) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Baynes Rule 10b5-1 Trading Plan provides for the exercise of 37,230 stock options and sale of underlying shares of our common stock pursuant to the terms of the plan between November 11, 2024 and December 31, 2025.
Daniel Rabinowitz
chief legal officer
Adopted 10b5-1 plan Jun 14, 2024 10-Q Nov 12, 2024
What the company wrote
On June 14, 2024 , Daniel Rabinowitz , our chief legal officer , adopted a trading arrangement for the sale of shares of our common stock (a “Rule 10b5-1 Trading Plan”) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Rabinowitz’s Rule 10b5-1 Trading Plan provides for the sale of 26,131 shares of our common stock pursuant to the terms of the plan between December 15, 2024 and August 15, 2026.
Mike Brophy
chief financial officer
Adopted 10b5-1 plan Jun 14, 2024 10-Q Nov 12, 2024
What the company wrote
On June 14, 2024 , Mike Brophy , our chief financial officer , adopted a trading arrangement for the sale of shares of our common stock (a “Rule 10b5-1 Trading Plan”) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Brophy’s Rule 10b5-1 Trading Plan provides for the potential sale of up to 109,293 shares of our common stock pursuant to the terms of the plan between February 2, 2025 and February 1, 2026.
Jonathan Sheena
co-founder and a member of our board of directors
Adopted 10b5-1 plan Dec 12, 2023 10-K Feb 29, 2024
Steve Chapman
chief executive officer
Ended other arrangement Dec 8, 2023 10-K Feb 29, 2024
Steve Chapman
chief executive officer
Ended 10b5-1 plan Oct 11, 2023 10-Q Nov 9, 2023
What the company wrote
On October 11, 2023, Steve Chapman, our chief executive officer, terminated a trading arrangement for the sale of the Company's common stock. Such trading arrangement was not intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c), but complied with the then-applicable requirements of Rule 10b5-1(c) when adopted in September 2021. Such trading arrangement provided for the sale of up to 50,910 shares between April 1, 2022 and May 1, 2022.
Herm Rosenman
a member of the Company’s board of directors
Adopted 10b5-1 plan May 19, 2023 10-Q Aug 4, 2023
What the company wrote
On May 19, 2023, Herm Rosenman, a member of the Company’s board of directors, adopted a trading arrangement for the sale of securities of the Company’s common stock (a “Rule 10b5-1 Trading Plan”) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Rosenman’s Rule 10b5-1 Trading Plan provides for the exercise of 93,901 stock options and sale of underlying shares of common stock pursuant to the terms of the plan, between August 18, 2023 and February 23, 2024.
Daniel Rabinowitz
chief legal officer and secretary
Adopted plan – 10-Q May 9, 2025
What the company wrote
On March 14, 2025, Daniel Rabinowitz, our chief legal officer and secretary, amended a Rule 10b5-1 Trading Plan to provide for the sale of 19,908 shares of our common stock pursuant to the terms of the plan between June 13, 2025 and August 15, 2026.
Matthew Rabinowitz
co-founder and executive chairman
Adopted 10b5-1 plan – 10-Q May 9, 2025
What the company wrote
On March 14, 2025, Matthew Rabinowitz, our co-founder and executive chairman, adopted a trading arrangement for the sale of securities of the Company’s common stock (a “Rule 10b5-1 Trading Plan”) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Dr. Rabinowitz’s Rule 10b5-1 Trading Plan provides for the sale of 80,000 shares of common stock pursuant to the terms of the plan between June 13, 2025 and December 13, 2025.
Roy Baynes
member of the Company's board of directors
Adopted 10b5-1 plan – 10-Q Nov 5, 2026
What the company wrote
On September 14 2026, Roy Baynes, a member of the Company's board of directors, adopted a Rule 10b5-1 Trading Plan that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Baynes’ Rule 10b5-1 Trading Plan provides for the exercise of up to 6,869 stock options and sale of underlying shares of common stock pursuant to the terms of the plan, between December 14, 2026 and December 15, 2027.
Steve Chapman
chief executive officer
Adopted plan – 10-K Feb 28, 2025
What the company wrote
​ On November 26, 2024, Solomon Moshkevich, our president, clinical diagnostics, adopted a Rule 10b5-1 Trading Plan that provides for the sale of up to 66,000 shares of our common stock pursuant to the terms of the plan between March 4, 2025 and November 30, 2026. ​ On December 2, 2024, Steve Chapman, our chief executive officer, amended a Rule 10b5-1 Trading Plan to provide for the potential sale of up to 395,452 shares of our common stock and the exercise of 156,825 stock options and sale of underlying shares of our common stock, pursuant to the terms of the plan between March 5, 2025 and November 30, 2026. A significant portion of the shares subject to the plan would not be sold unless the Company achieves specified performance targets.
Show the other 21 plans

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 10, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Nov 3, 2026 MICHAEL BROPHY
Officer
470 $178K
Nov 2, 2026 JOHN FESKO
OFFICER
291 $121K
Nov 2, 2026 SOLOMON MOSHKEVICH
OFFICER
405 $168K
Nov 2, 2026 STEVEN L CHAPMAN
Officer, Director
2,866 $1.2M
Nov 2, 2026 SOLOMON MOSHKEVICH
Officer
3,000 $1.2M
Nov 2, 2026 DANIEL RABINOWITZ
OFFICER
330 $137K
Nov 2, 2026 STEVEN CHAPMAN
OFFICER, DIRECTOR
903 $374K
Nov 2, 2026 MICHAEL BROPHY
OFFICER
313 $130K
Nov 2, 2026 JONATHAN SHEENA
DIRECTOR
108 $45K
Nov 2, 2026 MATTHEW RABINOWITZ
DIRECTOR
722 $299K
Oct 30, 2026 MICHAEL BROPHY
Officer
1,906 $831K
Oct 28, 2026 JOHN FESKO
OFFICER
917 $377K
Oct 28, 2026 SOLOMON MOSHKEVICH
OFFICER
1,185 $487K
Oct 28, 2026 MICHAEL BROPHY
Officer
1,178 $484K
Oct 28, 2026 DANIEL RABINOWITZ
OFFICER
988 $406K
Oct 28, 2026 STEVEN CHAPMAN
OFFICER, DIRECTOR
3,499 $1.4M
Oct 28, 2026 MICHAEL BROPHY
OFFICER
1,222 $502K
Oct 28, 2026 JONATHAN SHEENA
DIRECTOR
191 $78K
Oct 27, 2026 JOHN FESKO
OFFICER
771 $312K
Oct 27, 2026 SOLOMON MOSHKEVICH
OFFICER
997 $404K
Oct 27, 2026 DANIEL RABINOWITZ
OFFICER
873 $353K
Oct 27, 2026 JONATHAN SHEENA
DIRECTOR
287 $116K
Oct 27, 2026 MATTHEW RABINOWITZ
DIRECTOR
1,697 $687K
Oct 27, 2026 STEVEN CHAPMAN
OFFICER, DIRECTOR
2,236 $905K
Oct 27, 2026 MICHAEL BROPHY
OFFICER
771 $312K
Oct 21, 2026 Sheena Jonathan
Director
9,450 $3.9M
Oct 15, 2026 MATTHEW RABINOWITZ
Director, Officer
50,000 $19.7M
Oct 1, 2026 STEVEN L CHAPMAN
Officer, Director
1,273 $526K
Oct 1, 2026 SOLOMON MOSHKEVICH
Officer
3,000 $1.2M
Sep 23, 2026 Sheena Jonathan
Director
21,064 $8.2M
Sep 15, 2026 TINKERBELLE II TR U/A DTD 10/22/2021
Officer, Director
2,000 $700K
Sep 11, 2026 MATTHEW RABINOWITZ
Director, Officer
200,000 $65.2M
Sep 2, 2026 SOLOMON MOSHKEVICH
OFFICER
– –
Sep 1, 2026 STEVEN L CHAPMAN
Officer, Director
1,698 $545K
Sep 1, 2026 SOLOMON MOSHKEVICH
Officer
3,000 $962K
Aug 7, 2026 TINKERBELLE II TR U/A DTD 10/22/2021
Officer, Director
2,000 $642K
Aug 7, 2026 Sheena Jonathan
Director
18,000 $6.0M
Aug 4, 2026 MICHAEL BROPHY
Officer
478 $129K
Aug 3, 2026 JOHN FESKO
OFFICER
292 $78K
Aug 3, 2026 SOLOMON MOSHKEVICH
OFFICER
405 $108K
Aug 3, 2026 STEVEN L CHAPMAN
Officer, Director
1,894 $503K
Aug 3, 2026 SOLOMON MOSHKEVICH
Officer
3,000 $796K
Aug 3, 2026 DANIEL RABINOWITZ
OFFICER
330 $88K
Aug 3, 2026 STEVEN CHAPMAN
OFFICER, DIRECTOR
1,167 $312K
Aug 3, 2026 MICHAEL BROPHY
OFFICER
313 $84K
Aug 3, 2026 JONATHAN SHEENA
OFFICER
108 $29K
Aug 3, 2026 MATTHEW RABINOWITZ
OFFICER, DIRECTOR
722 $193K
Jul 29, 2026 MICHAEL BROPHY
Officer
1,863 $470K
Jul 28, 2026 JOH N FESKO
OFFICER
917 $237K
Jul 28, 2026 SOLOMON MOSHKEVICH
OFFICER
1,185 $306K
Jul 28, 2026 MICHAEL BROPHY
Officer
1,178 $304K
Jul 28, 2026 DANIEL RABINOWITZ
OFFICER
988 $255K
Jul 28, 2026 STEVEN CHAPMAN
OFFICER, DIRECTOR
3,525 $910K
Jul 28, 2026 MICHAEL BROPHY
OFFICER
1,222 $315K
Jul 28, 2026 JONATHAN SHEENA
DIRECTOR
188 $49K
Jul 27, 2026 JOHN FESKO
OFFICER
772 $202K
Jul 27, 2026 SOLOMON MOSHKEVICH
OFFICER
998 $261K
Jul 27, 2026 DANIEL RABINOWITZ
OFFICER
873 $229K
Jul 27, 2026 STEVEN CHAPMAN
OFFICER, DIRECTOR
2,163 $567K
Jul 27, 2026 MICHAEL BROPHY
OFFICER
772 $202K
Jul 27, 2026 JONATHAN SHEENA
DIRECTOR
285 $75K
Jul 27, 2026 MATTHEW RABINOWITZ
DIRECTOR, OFFICER
1,697 $445K
Jul 15, 2026 ROWAN EMMA CHAPMAN
Director
135 $37K
Jul 15, 2026 Sheena Jonathan
Director
1,500 $413K
Jul 13, 2026 Sheena Jonathan
Director
9,450 $2.5M
Jul 6, 2026 TINKERBELLE II TR U/A DTD 10/22/2021
Officer, Director
1,000 $280K
Jul 1, 2026 DANIEL RABINOWITZ
Officer
16,800 $4.6M
Jul 1, 2026 SOLOMON MOSHKEVICH
Officer
3,000 $819K
Jun 24, 2026 DANIEL RABINOWITZ
Officer
33,600 $7.9M
Jun 24, 2026 HERMAN ROSENMAN
Director
16,530 $4.1M
Jun 16, 2026 ROWAN EMMA CHAPMAN
Director
2,964 $643K
Jun 12, 2026 MATTHEW RABINOWITZ
Director, Officer
100,000 $21.9M
Jun 5, 2026 GAIL MARCUS
Director
11,000 $2.4M
Jun 4, 2026 STEVEN L CHAPMAN
Officer, Director
41,124 $9.1M
Jun 1, 2026 BV369 TRUST
Affiliate
78,000 $17.2M
Jun 1, 2026 SOLOMON MOSHKEVICH
Officer
3,000 $655K
May 4, 2026 MICHAEL BROPHY
Officer
482 $100K
May 1, 2026 SOLOMON MOSHKEVICH
Officer
3,000 $610K
Apr 29, 2026 MICHAEL BROPHY
Officer
3,070 $615K
Apr 1, 2026 SOLOMON MOSHKEVICH
Officer
3,000 $607K
Mar 20, 2026 Sheena Jonathan
Director
6,000 $1.2M
Mar 18, 2026 Sheena Jonathan
Director
12,441 $2.5M
Mar 13, 2026 ROWAN EMMA CHAPMAN
Director
122 $23K
Mar 12, 2026 MATTHEW RABINOWITZ
Director, Officer
200,000 $39.3M
Mar 6, 2026 DANIEL RABINOWITZ
Officer
16,798 $3.3M
Mar 2, 2026 STEVEN L CHAPMAN
Officer, Director
3,950 $790K
Mar 2, 2026 SOLOMON MOSHKEVICH
Officer
3,000 $600K
Feb 3, 2026 MICHAEL BROPHY
Officer
5,671 $1.3M
Feb 2, 2026 STEVEN L CHAPMAN
Officer, Director
85,299 $19.7M
Feb 2, 2026 SOLOMON MOSHKEVICH
Officer
3,000 $694K
Jan 29, 2026 MICHAEL BROPHY
Officer
1,867 $440K
Jan 28, 2026 MICHAEL BROPHY
Officer
1,176 $283K
Jan 21, 2026 MICHAEL BROPHY
Officer
36,573 $8.6M
Jan 2, 2026 SOLOMON MOSHKEVICH
Officer
2,951 $676K
Jan 2, 2026 STEVEN L CHAPMAN
Officer, Director
3,848 $881K
Dec 19, 2025 Sheena Jonathan
Director
4,500 $990K
Dec 17, 2025 Sheena Jonathan
Director
9,210 $2.1M
Dec 12, 2025 Herm Rosenman Trust
Board member
48,419 $11.3M
Dec 12, 2025 SOLOMON MOSHKEVICH
Officer
4,692 $1.1M
Dec 5, 2025 ROWAN EMMA CHAPMAN
Director
4,366 $1.1M
Dec 1, 2025 STEVEN L CHAPMAN
Officer, Director
4,400 $1.0M
Dec 1, 2025 SOLOMON MOSHKEVICH
Officer
3,000 $714K
Nov 24, 2025 BV369 TRUST
Affiliate
75,000 $17.7M
Nov 20, 2025 ROY BAYNES
Director
7,668 $1.7M
Nov 20, 2025 Sheena Jonathan
Director
10,000 $2.3M
Nov 19, 2025 ROY BAYNES
Director
5,112 $1.1M
Show the other 98 notices

From the Form 144 XML filed with the SEC, since Nov 19, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/NTRA/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.